Title:Why Antidiabetic Vanadium Complexes are Not in the Pipeline of “Big Pharma” Drug Research? A Critical Review
Volume: 23
Issue: 25
Author(s): Thomas Scior, Jose Antonio Guevara-Garcia, Quoc-Tuan Do, Philippe Bernard, Stefan Laufer
Affiliation:
关键词:
降糖药,类胰岛素,蛋白酪氨酸磷酸酶1B,钒配合物,形态,药物设计,分子建模。
摘要: Public academic research sites, private institutions as well as
small companies have made substantial contributions to the ongoing development
of antidiabetic vanadium compounds. But why is this endeavor not
echoed by the globally operating pharmaceutical companies, also known as
“Big Pharma”? Intriguingly, today’s clinical practice is in great need to improve
or replace insulin treatment against Diabetes Mellitus (DM). Insulin is
the mainstay therapeutically and economically. So, why do those companies
develop potential antidiabetic drug candidates without vanadium (vanadium-
free)? We gathered information about physicochemical and pharmacological
properties of known vanadium-containing antidiabetic compounds
from the specialized literature, and converted the data into explanations (arguments, the
“pros and cons”) about the underpinnings of antidiabetic vanadium. Some discoveries were
embedded in chronological order while seminal reviews of the last decade about the Medicinal
chemistry of vanadium and its history were also listed for further understanding. In
particular, the concepts of so-called “noncomplexed or free” vanadium species (i.e. inorganic
oxido-coordinated species) and “biogenic speciation” of antidiabetic vanadium complexes
were found critical and subsequently documented in more details to answer the question.